Recent studies suggest that LDN may help reduce systemic inflammation and support metabolic function, especially when combined with lifestyle interventions and other therapies. A 2021 systematic review noted LDN’s potential impact on immune modulation and insulin sensitivity in patients with obesity and chronic inflammation [1].

• Clients with metabolic challenges such as insulin resistance, PCOS, or metabolic syndrome
• Individuals struggling with emotional or stress-related eating patterns
• Patients managing inflammatory or autoimmune conditions, including Hashimoto’s (under supervision)
• Those experiencing a plateau on GLP-1 therapies or transitioning off them
• Clients seeking an affordable, long-term support option within a broader weight loss plan

• Typical Dose Range: 1.5 mg to 8 mg daily, titrated gradually
• Time to Results: Appetite and mood benefits may appear within weeks; weight and metabolic changes usually take 3–6 months
• Side Effects: Generally well tolerated; occasional nausea or vivid dreams
• Long-Term Use: Can be used as an ongoing part of a medically supervised weight loss plan [2]

GLP-1 receptor agonists (like Semaglutide) have gained popularity for their appetite-suppressing and glucose-regulating effects. LDN may complement these therapies by supporting inflammation reduction, helping regulate appetite-related behaviors, and addressing emotional eating triggers [3].

• LDN Alone: May benefit patients seeking moderate appetite regulation, mood support, or metabolic reinforcement—particularly in cases involving emotional or stress-related eating.
• LDN + GLP-1s: May enhance weight loss support by addressing inflammation, thyroid function, and cravings—potentially helping maintain metabolic balance during treatment [4].
• After GLP-1s: Useful for weight maintenance after discontinuing GLP-1 therapy [5].

1. Choubey A, et al. Low-dose naltrexone rescues inflammation and insulin resistance associated with hyperinsulinemia. J Biol Chem. 2020;295(49):16359–16369.
2. Younger J, Parkitny L, McLain D. The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clin Rheumatol. 2014;33(4):451–459.
3. Toljan K, Vrooman B. Low-dose naltrexone (LDN)—review of therapeutic utilization. Med Sci (Basel). 2018;6(4):82.
4. Cant R, Dalgleish AG, Allen RL. Naltrexone inhibits IL-6 and TNFα production in human immune cell subsets following stimulation with ligands for intracellular toll-like receptors. Front Immunol. 2017;8:809.
5. Hutchinson MR, et al. Non-stereoselective reversal of neuropathic pain by naloxone and naltrexone: involvement of toll-like receptor 4. Eur J Neurosci. 2008;28(1):20–29.
6. Raknes G, Småbrekke L. Low dose naltrexone in multiple sclerosis: effects on medication use. A quasi-experimental study. PLoS One. 2017;12(11):e0187423.
7. Wang X, Zhang Y, Peng Y, et al. Pharmacological characterization of the opioid inactive isomers (+)-naltrexone and (+)-naloxone as antagonists of toll-like receptor 4. Br J Pharmacol. 2016;173(5):856–869.